GlassScriptPhysician profile
Brian J Blumenstein
NPI 1194784645
$2,228.34
in general payments reported to CMS, 2019-2025
23 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $33.61 · 2021: $235 · 2022: $391 · 2023: $920 · 2024: $104 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.53 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.41 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Scientific Affairs, LLC | $194.16 | 2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $127.32 | 2019-2023 | Entyvio, Gattex |
| Endogastric Solutions, INC | $107.84 | 2021 | |
| Janssen Biotech, INC. | $93.41 | 2019-2023 | Stelara |
| Pfizer INC. | $89.04 | 2023 | |
| Celgene Corporation | $53.40 | 2023-2024 | Zeposia |
| Mauna Kea Technologies, INC. | $28.58 | 2022 | |
| Madrigal Pharmaceuticals | $27.07 | 2024 | Resmetirom |
| Organon LLC | $25.53 | 2023 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.54 | 2023 | Cyltezo |
| Ardelyx, INC. | $23.25 | 2023 | Ibsrela |
| Shionogi INC | $19.87 | 2019 | |
| Merck Sharp & Dohme LLC | $18.44 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $17.68 | 2023 | Pancreaze |
| Braintree Laboratories, INC. | $17.21 | 2023 | Suflave |
| Aimmune Therapeutics, INC. | $15.48 | 2025 | Zenpep |
| Amgen INC. | $14.94 | 2023 | Amjevita |
| Shire North American Group INC | $13.44 | 2019 | |
| Medtronic, INC. | $12.37 | 2021 | |
| Allergan, INC. | $11.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,636.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Blumenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.